LONDON – Vantia Therapeutics Ltd. has raised £8 million (US$13.1 million) for the development of a portfolio of plasma kallikrein inhibitors it is spinning out into a new company co-founded with diabetes experts at Harvard Medical School. Read More
TSRL Inc. is not a new company by any stretch of the imagination. It has been a going concern since 1986, when it was founded as a spinout from the University of Michigan. Read More
Santarus Inc., of San Diego, and Depomed Inc., of Menlo Park, Calif., inked a new commercialization deal for Glumetza (metformin hydrochloride extended-release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement signed in July 2008. The new terms call for Santarus to record revenue from Glumetza sales in the U.S., effective Sept. 1. Read More
Mesoblast Ltd., of Melbourne, Australia, reported that the first lumbar disc procedure was successfully performed in the Phase II trial of its adult mesenchymal precursor cell (MPC) product. Read More
An FDA approval, particularly if it's the first one for a small-cap biotech, usually sends the stock soaring, but Seattle Genetics Inc. saw only a modest gain late Friday, despite a sooner-than-expected nod for Adcetris (brentuximab vedotin), its anti-CD30 antibody-drug conjugate for two types of lymphoma. (See BioWorld Today, Aug. 22, 2011.) Read More
LONDON – The latest spinout to emerge from GlaxoSmithKline (GSK) plc's restructuring has raised £10 million (US$16.4 million) from venture capital (VC) investors to fund the development of drug treatments for hearing loss and tinnitus. Read More
